Toxicology and Carcinogenesis Study of Senna in C3B6.129F1-Trp53 tm1Brd N12 Haploinsufficient Mice

Toxicologic Pathology

Volumn 41, Issue 5, 2013, Pages 770-778

  Surh, Inok ^a   Brix, Amy ^a,b   French, John E ^a   Collins, Bradley J ^a   Sanders, J Michael ^a   Vallant, Molly ^a   Dunnick, June K ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

Author keywords

carcinogenesis; large intestine; laxative; senna; toxicity; Trp53

Indexed keywords

LAXATIVE; PROTEIN P53; RHEIN ANTHRONE; SENNA EXTRACT; SENNOSIDE A; SENNOSIDE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CECUM; COLON; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; EPITHELIUM HYPERPLASIA; FEMALE; HAPLOINSUFFICIENCY; INTESTINE FLORA; INTESTINE INJURY; INTESTINE MUCOSA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENNA; WILD TYPE;

CARCINOGENESIS; LARGE INTESTINE.; LAXATIVE; SENNA; TOXICITY; TRP53;

ANIMALS; BODY WEIGHT; CARCINOGENICITY TESTS; FEMALE; HAPLOINSUFFICIENCY; INTESTINE, LARGE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; SENNA EXTRACT; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

BACTERIA (MICROORGANISMS); MUS; SENNA; SENNA ALEXANDRINA;

EID: 84879491299     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623312464304     Document Type: Article

References (67)

1. Al-Yahya M. A. Al-Farhan A. H. Adam S. E. (2002). Toxicological interactions of Cassia senna and Nerium oleander in the diet of rats. Am J Chin Med 30, 579–87.
2. Beuers U. Spengler U. Pape G. R. (1991). Hepatitis after chronic abuse of senna. Lancet 337, 372–73.
3. Blumenthal M., Goldberg A., Brinckmann J. (2000). Herbal Medicine: Expanded Commission E Monographs. pp. 341–45. Austin, TX: American Botanical Council.
4. Borrelli F. Capasso R. Aviello G. Di Carlo G. Izzo A. A. Mascolo N. Capasso F. (2005). Senna and the formation of aberrant crypt foci and tumors in rats treated with azoxymethane. Phytomedicine 12, 501–505; discussion 505.
5. Boyd J. T. Doll R. (1954). Gastro-intestinal cancer and the use of liquid paraffin. Br J Cancer 8, 231–237.
6. Brown J. P. Dietrich P. S. (1979). Mutagenicity of anthraquinone and benzanthrone derivatives in the Salmonella/microsome test: Activation of anthraquinone glycosides by enzymic extracts of rat cecal bacteria. Mutat Res 66, 9–24.
7. Brusick D. Mengs U. (1997). Assessment of the genotoxic risk from laxative senna products. Environ Mol Mutagen 29, 1–9.
8. Bryant-Waugh R. Turner H. East P. Gamble C. Mehta R. (2006). Misuse of laxatives among adult outpatients with eating disorders: Prevalence and profiles. Int J Eat Disord 39, 404–409.
9. Cance J. D. Ashley O. S. Penne M. A. (2005). Unhealthy weight control behaviors and MDMA (Ecstasy) use among adolescent females. J Adolesc Health 37, 409.
10. Donehower L. A. Harvey M. Slagle B. L. McArthur M. J. Montgomery C. A. Jr Butel J. S. Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–221.
11. Donehower L. A. Harvey M. Vogel H. McArthur M. J. Montgomery C. A. Jr Park S. H. Thompson T. Ford R. J. Bradley A. (1995). Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 14, 16–22.
12. Dreessen M. Eyssen H. Lemli J. (1981). The metabolism of sennosides A and B by the intestinal microflora: In vitro and in vivo studies on the rat and the mouse. J Pharm Pharmacol 33, 679–81.
13. Dunnick J. K. Hardisty J. F. Herbert R. A. Seely J. C. Furedi-Machacek E. M. Foley J. F. Lacks G. D. Stasiewicz S. French J. E. (1997). Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/−) mice. Toxicol Pathol 25, 533–40.
14. Franz G. (1993). The senna drug and its chemistry. Pharmacology, 47 Suppl 1, 2–6.
15. Freireich E. J. Gehan E. A. Rall D. P. Schmidt L. H. Skipper H. E. (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50, 219–44.
16. French J. Storer R. D. Donehower L. A. (2001). The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol 29 Suppl, 24–29.
17. French J. E. (2004). Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus. IARC Sci Publ 2004, 271–87.
18. French J. E. Lacks G. D. Trempus C. Dunnick J. K. Foley J. Mahler J. Tice R. R. Tennant R. W. (2001). Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/−) mouse tumors is carcinogen-and tissue-dependent. Carcinogenesis 22, 99–106.
19. Heidemann A. Miltenburger H. G. Mengs U. (1993). The genotoxicity status of senna. Pharmacology 47 Suppl 1, 178–86.
20. Heidemann A. Volkner W. Mengs U. (1996). Genotoxicity of aloeemodin in vitro and in vivo. Mutat Res 367, 123–33.
21. Helin T. Makinen-Kiljunen S. (1996). Occupational asthma and rhinoconjunctivitis caused by senna. Allergy 51, 181–84.
22. Hu Y. Le Leu R. K. Young G. P. (2005). Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. Int J Cancer 115, 561–67.
23. Kawasaki Y. Goda Y. Yoshihira K. (1992). The mutagenic constituents of Rubia tinctorum. Chem Pharm Bull (Tokyo) 40, 1504–09.
24. Kleibeuker J. H. Cats A. Zwart N. Mulder N. H. Hardonk M. J. de Vries E. G. (1995). Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst 87, 452–53.
25. Lemli J. (1988). Metabolism of sennosides–an overview. Pharmacology 36 Suppl 1, 126–28.
26. Lemli J. Lemmens L. (1980). Metabolism of sennosides and rhein in the rat. Pharmacology 20 Suppl 1, 50–57.
27. Leng-Peschlow E. (1986). Dual effect of orally administered sennosides on large intestine transit and fluid absorption in the rat. J Pharm Pharmacol 38, 606–10.
28. Leng-Peschlow E. (1992). Senna and its rational use. Pharmacology 44 Suppl 1, 1–52.
29. Lubet R. A. Zhang Z. Wiseman R. W. You M. (2000). Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 26, 581–93.
30. Lyden-Sokolowski A. Nilsson A. Sjoberg P. (1993). Two-year carcinogenicity study with sennosides in the rat: Emphasis on gastro-intestinal alterations. Pharmacology 47 Suppl 1, 209–15.
31. Makena P. S. Chung K. T. (2007). Effects of various plant polyphenols on bladder carcinogen benzidine-induced mutagenicity. Food Chem Toxicol 45, 1899–909.
32. Marks G. B. Salome C. M. Woolcock A. J. (1991). Asthma and allergy associated with occupational exposure to ispaghula and senna products in a pharmaceutical work force. Am Rev Respir Dis 144, 1065–69.
33. Mascolo N. Mereto E. Borrelli F. Orsi P. Sini D. Izzo A. A. Massa B. Boggio M. Capasso F. (1999). Does senna extract promote growth of aberrant crypt foci and malignant tumors in rat colon? Dig Dis Sci 44, 2226–30.
34. Mengs U. (1988). Toxic effects of sennosides in laboratory animals and in vitro. Pharmacology 36 Suppl 1, 180–87.
35. Mengs U. Grimminger W. Krumbiegel G. Schuler D. Silber W. Volkner W. (1999). No clastogenic activity of a senna extract in the mouse micronucleus assay. Mutat Res 444, 421–26.
36. Mengs U. Heidemann A. (1993). Genotoxicity of sennosides and rhein in vitro and in vivo. Med Sci Res 21, 749–50.
37. Mengs U. Mitchell J. McPherson S. Gregson R. Tigner J. (2004). A 13-week oral toxicity study of senna in the rat with an 8-week recovery period. Arch Toxicol 78, 269–75.
38. Mereto E. Ghia M. Brambilla G. (1996). Evaluation of the potential carcinogenic activity of Senna and Cascara glycosides for the rat colon. Cancer Lett 101, 79–83.
39. Mitchell J. M. Mengs U. McPherson S. Zijlstra J. Dettmar P. Gregson R. Tigner J. C. (2006). An oral carcinogenicity and toxicity study of senna (Tinnevelly senna fruits) in the rat. Arch Toxicol 80, 34–44.
40. Mladenova D. Daniel J. J. Dahlstrom J. E. Bean E. Gupta R. Pickford R. Currey N. Musgrove E. A. Kohonen-Corish M. R. (2011). The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 60, 350–360.
41. Mond J. M. Hay P. J. Rodgers B. Owen C. Mitchell J. E. (2006). Correlates of self-induced vomiting and laxative misuse in a community sample of women. J Nerv Ment Dis 194, 40–46.
42. Moussally K. Oraichi D. Berard A. (2009). Herbal products use during pregnancy: prevalence and predictors. Pharmacoepidemiol Drug Saf 18, 454–61.
43. Mueller S. O. Stopper H. Dekant W. (1998). Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes. Bioactivation to genotoxic metabolites. Drug Metab Dispos 26, 540–46.
44. Mukhopadhyay M. J. Saha A. Dutta A. De B. Mukherjee A. (1998). Genotoxicity of sennosides on the bone marrow cells of mice. Food Chem Toxicol 36, 937–940.
45. Nesslany F. Simar-Meintieres S. Ficheux H. Marzin D. (2009). Aloe-emodin-induced DNA fragmentation in the mouse in vivo comet assay. Mutat Res 678, 13–19.
46. National Institutes of Health (U.S.). Office of Laboratory Animal Welfare (2002). Public health service policy on humane care and use of laboratory animals. Office of laboratory animal welfare, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.
47. Novartis. (2010). Accessed on March 17, 2010. Product informatoin for ex-lax maximum strength. http://ex-lax.com/product-max.shtml.
48. Occhipinti K. E. Di Palma J. A. (2009). How to choose the best preparation for colonoscopy. Nat Rev Gastroenterol Hepatol 6, 279–86.
49. Pritchard J. B. French J. E. Davis B. J. Haseman J. K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111, 444–54.
50. Sandnes D. Johansen T. Teien G. Ulsaker G. (1992). Mutagenicity of crude senna and senna glycosides in Salmonella typhimurium. Pharmacol Toxicol 71, 165–72.
51. Satia J. A. Littman A. Slatore C. G. Galanko J. A. White E. (2009). Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev 18, 1419–28.
52. Seybold U. Landauer N. Hillebrand S. Goebel F. D. (2004). Senna-induced hepatitis in a poor metabolizer. Ann Intern Med 141, 650–51.
53. Shah N. D. Chitkara D. K. Locke G. R. Meek P. D. Talley N. J. (2008). Ambulatory care for constipation in the United States, 1993-2004. Am J Gastroenterol 103, 1746–53.
54. Siegers C. P. Siemers J. Baretton G. (1993). Sennosides and aloin do not promote dimethylhydrazine-induced colorectal tumors in mice. Pharmacology 47 Suppl 1, 205–208.
55. Siegers C. P. von Hertzberg-Lottin E. Otte M. Schneider B. (1993). Anthranoid laxative abuse–a risk for colorectal cancer? Gut 34, 1099–101.
56. Smitherman L. C. Janisse J. Mathur A. (2005). The use of folk remedies among children in an urban black community: Remedies for fever, colic, and teething. Pediatrics 115, e297–304.
57. Soussi T. Beroud C. (2001). Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1, 233–40.
58. Spiller H. A. Winter M. L. Weber J. A. Krenzelok E. P. Anderson D. L. Ryan M. L. (2003). Skin breakdown and blisters from senna-containing laxatives in young children. Ann Pharmacother 37, 636–39.
59. Tennant R. W. French J. E. Spalding J. W. (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103, 942–50.
60. Toyoda K. Nishikawa A. Furukawa F. Kawanishi T. Hayashi Y. Takahashi M. (1994). Cell proliferation induced by laxatives and related compounds in the rat intestine. Cancer Lett 83, 43–49.
61. Tozzi F. Thornton L. M. Mitchell J. Fichter M. M. Klump K. L. Lilenfeld L. R. Reba L. Strober M. Kaye W. H. Bulik C. M. (2006). Features associated with laxative abuse in individuals with eating disorders. Psychosom Med 68, 470–77.
62. U.S. Food and Drug Administration. (1999). Laxative Drug Products for Over-the Counter Human Use. Federal Register 64, 4535–40.
63. van Gorkom B. A. Karrenbeld A. van Der Sluis T. Koudstaal J. de Vries E. G. Kleibeuker J. H. (2000). Influence of a highly purified senna extract on colonic epithelium. Digestion 61, 113–20.
64. Vanderperren B. Rizzo M. Angenot L. Haufroid V. Jadoul M. Hantson P. (2005). Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother 39, 1353–57.
65. Westendorf J. Marquardt H. Poginsky B. Dominiak M. Schmidt J. (1990). Genotoxicity of naturally occurring hydroxyanthraquinones. Mutat Res 240, 1–12.
66. Yamauchi K. Yagi T. Kuwano S. (1993). Suppression of the purgative action of rhein anthrone, the active metabolite of sennosides A and B, by calcium channel blockers, calmodulin antagonists and indomethacin. Pharmacology 47 Suppl 1, 22–31.
67. Zuckerman V. Wolyniec K. Sionov R. V. Haupt S. Haupt Y. (2009). Tumour suppression by p53: The importance of apoptosis and cellular senescence. J Pathol 219, 3–15.